Etanercept

• Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA) Pending
  2025-520923-25-00 Phase III 3 countries Duke Clinical Research Institute
• IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO) Pending
  2025-524834-24-00 Phase I/II 1 country Centre Hospitalier Universitaire De Nantes
• The OASE study Pending
  2026-525221-21-01 Phase IV 1 country Aalborg University Hospital
• Discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors Pending
  2026-525316-33-00 Phase IV 1 country Sint Maartenskliniek Stichting
• The Treat-JIA trial Pending
  2026-525611-13-00 Phase IV 1 country Oslo Universitetssykehus HF
• Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized cli… Recruiting
  2024-514732-24-00 Phase IV 7 countries IRCCS Istituto Giannina Gaslini
• A randomized trial comparing efficacy and safety of etanercept and methotrexate in giant cell arteritis (EFFECTA) Recruiting
  2023-506623-29-01 Phase II 1 country Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
• Combination of baricitinib and anti-TNF in rheumatoid arthritis Recruiting
  2024-511442-39-00 Phase III 1 country Centre Hospitalier Universitaire De Bordeaux
• MOVE-JIA trial Recruiting
  2024-513017-12-00 Phase IV 1 country Oslo University Hospital HF
• Study of the efficacy and safety of etanercept treatment in patients with SAPHO syndrome Recruiting
  2024-516919-25-00 Phase II/III 1 country Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. E…
• Comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS Recruiting
  2023-505051-43-00 Phase III 1 country Giannina Gaslini Institute For Scientific Hospitalization And Care
• The 3TR Molecular Pathobiology-Driven Precision Therapy in RA (3TR Precis-The-RA) study Recruiting
  2022-502021-18-00 Phase IV 5 countries Queen Mary University Of London
• An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting
  2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
• RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting
  2024-516704-41-00 Phase III/IV 1 country Les Hopitaux Universitaires De Strasbourg
• Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point… Ended
  2024-511530-12-01 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Trial of efficacy and safety of MC0518 versus best available therapy in patients with steroid-refractory acute graft versus host disease Ended
  2023-503952-28-00 Phase II 5 countries Medac Gesellschaft fuer klinische Spezialprapaerate mbH
• A randomized, two-armed, single-blind, parallel, active controlled, and non-inferiority clinical trial to Compare Efficacy and Safety of ant… Ended
  2024-515557-22-00 Phase IV 1 country Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
• Study to see how good and safe Tildrakizumab is in children aged 6 to under 18 years of age with skin patches Ended
  2023-504447-14-00 Phase II/III 4 countries Sun Pharmaceutical Industries Limited
• A Study of Efficacy, Safety, and Pharmacokinetics of Guselkumab in the Treatment of Chronic Plaque Psoriasis in Pediatric Participants Ended
  2023-503378-19-00 Phase III 5 countries Janssen - Cilag International
• A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in… Ended
  2024-510826-16-00 Phase III 4 countries Mabxience Research S.L.
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 Phase IV 15 countries Eli Lilly & Co.
• RCT part: COBRA-Slim with or without fast access to TNF blockade for remission induction in early RA. LTE part: Long Term observational fol… Ended
  2023-510189-28-00 Phase IV 1 country UZ Leuven
• TOFA-PREDICT Ended
  2024-510903-12-00 Phase IV 1 country Universitair Medisch Centrum Utrecht

Showing 1–23 of 23 trials